Savant HWP, Inc., ("Savant") develops pharmaceutical products that improve health, maintain wellness and prevent disease. We identify undervalued opportunities to create innovative products in areas where our work has the greatest impact, including addiction medicine and neglected diseases like Chagas disease and leishmaniasis that are emerging in the U.S. population and endemic in other parts of the world.

Our leadership team of proven innovators has more than a century and a half of combined experience bringing new medicines to market. We focus on quickly and cost-efficiently building value in the projects we undertake, to support high-value corporate partnering and value creation for our shareholders.

**Development Program: Addiction Medicine**

18-MC (18-methoxycoronaridine) is an orally active small molecule that uniquely targets the brain mechanism underlying all forms of addiction – the extreme fluctuations of dopamine that lead to drug addiction or other obsessive craving.

- Different mechanism of action from all current anti-addiction medications
- Only agent shown effective in preclinical models against drug craving, including cue-induced craving
- Preclinical research suggests usefulness in wide range of addictions: cocaine, opioids, alcohol, methamphetamine, and even fatty/sugary foods
- Initial first-in-human testing initiated by Savant’s South American partner, showing positive safety profile for single oral dose in healthy volunteers. Safety studies continue.
- $6.8 million support to date from National Institute on Drug Abuse; potential for up to $40 million additional NIDA support for cocaine clinical trials.
- Additional global health indication for compound: leishmaniasis, under development by South American partner
- NIDA estimates the market potential for a first-in-class treatment for cocaine addiction at $1.2 billion annual revenue.

**Development Program: Chagas Disease**

HWP-002 is an undisclosed compound with demonstrated efficacy against Chagas Disease parasite (*Trypanosoma cruzi*) which offers a highly efficient pathway to market approval.

- Addresses rapidly growing US population of those chronically infected (300,000 (CDC estimate 2012)) as well as those with new, primary infections, an emerging risk associated with warming climate.
- Up to 30% of those chronically infected -- often without knowing it -- develop cardiac alterations and up to 10% develop digestive, neurological or other morbidities for which treatment may be necessary.
- Currently available therapy for Chagas disease is long duration, associated with significant adverse events, and in the United States, there are no currently approved drugs to treat the disease.
- Savant plans to file a U.S. IND in 2015.
- Conservative annual $10 million combined human and veterinary market for successful therapeutic.
The Team

Savant HWP’s management team brings together decades of expertise in the biopharmaceutical industry as well as the field of addiction medicine in a leveraged effort to develop novel, innovative drug products to meet important medical needs in often neglected indications.

- **Stephen L Hurst, JD – Founder, Director, Chairman and CEO** -- former CBO of The Immune Tolerance Institute; consultant to The World Bank and BIO Ventures for Global Health; Founder, President & CEO of Sequential; multiple senior executive positions at Inhale Therapeutic Systems (now Nektar Therapeutics, Inc.)
- **Scott M. Freeman, MD – Founder, Director and President & CMO** – former VP of Clinical Development at Onyx Pharmaceuticals; Clinical Project Director at Schering-Plough Research Institute; academic appointments at Tulane University, University of Rochester and National Institutes of Health.
- **Terence D. Boardman, Ph.D. -- Founder and Executive Vice President, Process Development and Manufacturing** – partner in the Enterprise Catalyst Group; former VP Operations for Sequential, Inc.; former VP of Process Development and Manufacturing for Inhale Therapeutic Systems (now Nektar Therapeutics); former Managing Director of CCL Pharmaceuticals (UK-based contract pharmaceutical manufacturer); former senior scientist and manager at Fisons Pharmaceuticals (now Sanofi-Aventis).
- **Stanley D. Glick, PhD, MD – Scientific Founder** – Former Director of the Center for Neuro-pharmacology and Neuroscience, Albany Medical College, Albany, NY since 2000; previously Professor of Pharmacology at Mount Sinai School of Medicine.

The Company

Savant HWP is a virtually organized company headquartered in the San Francisco Bay Area. Since the company’s formation in 2009, Savant has raised approximately $6.8 million in grants from the National Institute of Drug Abuse.

Contacts:

Stephen L. Hurst, JD, President and CEO
Email: Info@savanthwp.com

Joan E. Kureczka
Ph: (415) 8212413
Email: JKureczka@savanthwp.com